NASDAQ
126.58USD
+2.66 (+2.15%)
We have scored 10 news catalysts on Palvella Therapeutics, Inc. (PVLA) over the past 12 months. The biggest single-day move next to one of them came Feb 26, 2026, when PVLA closed +15.3%: “Palvella Therapeutics Announces Pricing of Upsized Public Offering”. Coverage across the window leans positive (average ticker sentiment +0.77). Most of the impact sits in price momentum and forward growth expectations.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.8B
P/E
—
EPS
—
Beta
-0.17
52W range
68.96-161.38
Day range
122.82–128.48
Open
126.87
Prev close
123.92
Volume
245.7K
Avg volume
238.1K
Dividend
0.00
IPO
2015-01-02
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Palvella Therapeutics, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for PVLA: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
